A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC

Vaccine

Volumn 26, Issue 36, 2008, Pages 4731-4739

  McKenzie, Robin ^a,b   Darsley, Michael ^c,g   Thomas, Nicola ^c,g   Randall, Roger ^c   Carpenter, Colleen ^b,f   Forbes, Edrick ^b   Finucane, Mariel ^d   Sack, R Bradley ^e   Hall, Eric ^f   Bourgeois, August L ^b,h  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b Center for Immunization Research   (United States)

^c Acambis   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f NAVAL MEDICAL RESEARCH CENTER   (United States)

^g ACE BioSciences AS   (Denmark)

^h Enteric Vaccine Initiative   (United States)

Author keywords

Diarrhea; Enterotoxigenic E. coli; ETEC; Live attenuated vaccine; Oral vaccine

Indexed keywords

CERAVACX; ESCHERICHIA COLI VACCINE; LIVE VACCINE; PLACEBO; PTL 003;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BACTERIAL VIRULENCE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEVELOPING COUNTRY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ENTEROBACTER INFECTION; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES INCONTINENCE; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION PREVENTION; MALAISE; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAVELLER DIARRHEA; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; DEVELOPING COUNTRIES; DIARRHEA; DOUBLE-BLIND METHOD; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; VACCINES, ATTENUATED;

EID: 48649103259     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.064     Document Type: Article

References (20)

1. New frontiers in the development of vaccines against enterotoxinogenic (ETEC) and enterohaemorrhagic (EHEC) E. coli infections. Part I. Wkly Epidemiol Rec 1999 2;74(13):98-101.
2. Levine M.M., Nalin D.R., Hoover D.L., Bergquist E.J., Hornick R.B., and Young C.R. Immunity to enterotoxigenic Escherichia coli. Infect Immun 23 3 (1979) 729-736
3. Black R.E. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 11 2 (1993) 100-106
4. DuPont H.L., Olarte J., Evans D.G., Pickering L.K., Galindo E., and Evans D.J. Comparative susceptibility of Latin American and United States students to enteric pathogens. N Engl J Med 295 27 (1976) 1520-1521
5. Adachi J.A., Ericsson C.D., Jiang Z.D., DuPont M.W., Pallegar S.R., and DuPont H.L. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 185 11 (2002) 1681-1683
6. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 18 (2007) 3684-3691
7. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers'diarrhoea: a phase II, randomized, double-blind, placebo-controlled field trial. Lancet 371 (2008) 2019-2025
8. Sack D.A., Shimko J., Torres O., Bourgeois A.L., Francia D.S., Gustafsson B., et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to guatemala and mexico. Vaccine 25 22 (2007) 4392-4400
9. Bourgeois AL, Halpern J, Gustafsson B, Svennerholm A-M, Karnell A, Shimko J, et al. Oral vaccine for the prevention of Traveler's diarrhea due to enterotoxigenic Escherichia coli, 45th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, abstract #G-408, 2005.
10. Tacket C.O., Reid R.H., Boedeker E.C., Losonsky G., Nataro J.P., Bhagat H., et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 12 14 (1994) 1270-1274
11. Levine M.M. Fimbriae (pili) as vaccines. In: Lark D.L. (Ed). Protein-carbohydrate interactions in biological systems: the molecular biology of microbial pathogenicity (1986), Academic Press, London and Orlando 143
12. Turner A.K., Terry T.D., Sack D.A., Londono-Arcila P., and Darsley M.J. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun 69 8 (2001) 4969-4979
13. McKenzie R., Bourgeois A.L., Engstrom F., Hall E., Chang H.S., Gomes J.G., et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun 74 2 (2006) 994-1000
14. Levine M.M., Ristaino P., Marley G., Smyth C., Knutton S., Boedeker E., et al. Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun 44 2 (1984) 409-420
15. Ahren C., Jertborn M., and Svennerholm A.M. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun 66 7 (1998) 3311-3316
16. Savarino S.J., Hall E.R., Bassily S., Brown F.M., Youssef F., Wierzba T.F., et al. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE study group. J Infect Dis 179 1 (1999) 107-114
17. Wenneras C., Qadri F., Bardhan P.K., Sack R.B., and Svennerholm A.M. Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees. Infect Immun 67 12 (1999) 6234-6241
18. Carpenter C.M., Hall E.R., Randall R., McKenzie R., Cassels F., Diaz N., et al. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine 24 18 (2006) 3709-3718
19. Daley A., Randall R., Darsley M., Choudhry N., Thomas N., Sanderson I.R., et al. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut 56 11 (2007) 1550-1556
20. Rao M.R., Wierzba T.F., Savarino S.J., Abu-Elyazeed R., El-Ghoreb N., Hall E.R., et al. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea. J Infect Dis 191 4 (2005) 562-570